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Abstract
Background: The major marker utilized to monitor COPD patients is forced expiratory volume
in one second (FEV1). However, asingle measurement of FEV1 cannot reliably predict subsequent
decline. Recent studies indicate that T lymphocytes and eosinophils are important determinants of
disease stability in COPD. We therefore measured cytokine levels in the lung lavage fluid and
plasma of COPD patients in order to determine if the levels of T cell or eosinophil related
cytokines were predictive of the future course of the disease.
Methods: Baseline lung lavage and plasma samples were collected from COPD subjects with
moderately severe airway obstruction and emphysematous changes on chest CT. The study
participants were former smokers who had not had a disease exacerbation within the past six
months or used steroids within the past two months. Those subjects who demonstrated stable
disease over the following six months (ΔFEV1 % predicted = 4.7 ± 7.2; N = 34) were
retrospectively compared with study participants who experienced a rapid decline in lung function
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Respiratory Research 2009, 10:113 http://respiratory-research.com/content/10/1/113(ΔFEV1 % predicted = -16.0 ± 6.0; N = 16) during the same time period and with normal controls
(N = 11). Plasma and lung lavage cytokines were measured from clinical samples using the Luminex
multiplex kit which enabled the simultaneous measurement of several T cell and eosinophil related
cytokines.
Results and Discussion: Stable COPD participants had significantly higher plasma IL-2 levels
compared to participants with rapidly progressive COPD (p = 0.04). In contrast, plasma eotaxin-1
levels were significantly lower in stable COPD subjects compared to normal controls (p < 0.03). In
addition, lung lavage eotaxin-1 levels were significantly higher in rapidly progressive COPD
participants compared to both normal controls (p < 0.02) and stable COPD participants (p < 0.05).
Conclusion: These findings indicate that IL-2 and eotaxin-1 levels may be important markers of
disease stability in advanced emphysema patients. Prospective studies will need to confirm whether
measuring IL-2 or eotaxin-1 can identify patients at risk for rapid disease progression.
Background
Research has indicated that eosinophils[1] and T lym-
phocytes[2,3] are important determinants of disease sta-
bility in COPD patients. Given these studies, we sought to
determine if eosinophil or T cell related cytokine levels
measured from the lung lavage and plasma of advanced
COPD patients could predict the future clinical course of
their disease. Our analyses in this study were primarily
focused on the role of IL-2, IL-2R, RANTES and Eotaxin-1
as these cytokines are critical regulators of T cell and eosi-
nophil proliferation and migration[4,5]. Currently, there
are no tests that can reliably identify which patients are
more likely to deteriorate over time. Forced expiratory vol-
ume in one second (FEV1) is used to diagnose the stage of
chronic obstructive pulmonary disease (COPD) and to
predict COPD mortality [6,7]. However, FEV1 is a physio-
logic parameter that changes relatively slowly over time in
COPD patients[8] and a given value of FEV1 does not
accurately predict the short or long-term course of a
patient's disease. The discovery of new markers that would
correlate with disease severity and foretell progression
would not only enable clinicians to identify susceptible
patients but would also allow researchers, by monitoring
marker levels, to more readily identify therapies that may
have a beneficial effect on the outcome of this disease.
In this study, we retrospectively analyzed cytokine levels
in the lung lavage and plasma of participants that were
enrolled in the NIH-sponsored FORTE trial (Feasibility of
Retinoids for the Treatment of Emphysema). The study
participants were stable but advanced emphysema
patients who had not smoked or had a respiratory exacer-
bation for at least six months prior to study entry. At base-
line and before study drug treatment, lung lavage and
plasma samples were obtained from the study partici-
pants who subsequently underwent extensive lung testing
over a nine-month time period. To determine if eosi-
nophil or T cell cytokine levels were associated with the
rate of decline of lung function, we analyzed a subset of
participants who experienced a significant decline in lung
function (>10% decrease in % predicted FEV1 post-bron-
chodilator; n = 16) during the first six months of the
study. The results obtained from this group were com-
pared with study participants with stable disease (no
decrease in % predicted FEV1 post-bronchodilator; n =
34), age-matched controls (plasma samples; n = 11) and
non-age matched controls (lung lavage; n = 8).
Materials and methods
Selection Criteria for Study Participants
Emphysema subjects were FORTE study participants [9].
Entry criteria included age > 45 years, FEV1 25 to 80% of
predicted, diffusing capacity of the lung for carbon mon-
oxide (DLco) ≤ 80% of predicted, visual evidence of
emphysema occupying ≥ 10% of the lung on CT scan, and
willingness to undergo bronchoscopy. Participants were
excluded for a Karnofsky score < 70%; excessive airway
hyperreactivity; resting oxygen saturation < 90% or Pco2 >
Outline of Study MethodologyFigur 1
Outline of Study Methodology.
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months or tobacco within 6 months; hyperlipidemia; a
history of clinical depression; concurrent use of medica-
tions that alter the metabolism of retinoids; or other sig-
nificant illnesses including cancer, liver disease, or heart
failure. Women of child-bearing potential were required
to use two forms of contraception or abstinence. After
enrollment, baseline bronchoscopy, blood tests, Chest
CT, pulmonary function tests and quality of life assess-
ments were performed and then participants were rand-
omized to low dose all trans-retinoic acid (LD-ATRA; 1
mg/kg), high dose ATRA (HD-ATRA; 2 mg/kg), 13-cis
retinoic acid (13-cRA; 1 mg/kg) or placebo for six months
(Figure 1). This study utilized the baseline plasma analy-
ses that were obtained prior to study drug administration.
Importantly, drug treatment had no effect on ΔFEV1, CT
density score or health related quality of life in this
study[9]. Figure 2 demonstrates the distribution of rate of
decline of % predicted FEV1 over the first six months of
the study. Of the 148 study participants, nineteen experi-
enced an absolute decline of at least 10% in their pre-
dicted FEV1 over the first six months of the trial. Of these
nineteen participants, 16 had stored plasma samples
available for further analyses with the Luminex system
(ΔFEV1 % predicted = -16.0 ± 6.0). Since this study aimed
to compare eosinophil and T cell cytokine patterns
between subjects with progressive disease vs. stable COPD
subjects, we compared this group to a subset of FORTE
subjects who demonstrated disease stability during this
same time period (Δ % predicted FEV1 = 4.7 ± 7.2). Like-
wise, lavage samples from the rapid decliners (n = 8 for
lung lavage) were compared with lavage samples from
eleven randomly selected study participants with no
decline in % predicted FEV1 over the first six months.
Normal controls values for plasma (n = 11) and lung lav-
age (n = 8) were obtained from non-smoking volunteers
that had no significant respiratory disease. Of note, at the
nine month follow up time point, the rapid decliners con-
tinued to demonstrate a decreased % predicted FEV1 (-7.8
± 4.8) compared to the stable COPD participants (2.3 ±
5.1). Demographic data on all the study participants is
provided in Table 1, Table 2, Table 3 and Table 4. Written
consent was obtained from all study participants and the
institutional review boards of all of the participating cent-
ers approved the trial.
Distribution of Δ % Predicted FEV1 at the 6 Month Time PointFigure 2
Distribution of Δ % Predicted FEV1 at the 6 Month 
Time Point. The bar graph represents the frequency of dis-
tribution of Δ % predicted FEV1 at the six month time point. 
Most participants (approximately 63%) demonstrated stable 
disease with the % predicted FEV1 varying less than 5% from 
baseline. Less than 20% of participants had an absolute 
decline in % predicted FEV1 of 10% or greater.
Table 1: Demographics of Entire Cohort of FORTE Study 
Participants
FORTE Subjects
Mean Std
N 148
Age at Randomization, years 65.8 7.4
Gender, % male 58.1
Smoking HX, pack-years 57.8 29
BL Chronic cough, % subjects 24.5
BL StGeo Total Score 39.3 13.1
BL Post-BD %Pred FEV1 42.5 13.7
BL Post-BD %Pred FVC 80.1 15.7
Bronchodilator response, % changed 12.7 10.4
BL %Pred TLC 118.1 16.2
BL %Pred RV (meth A) 180.8 48.1
BL %Pred DLCO 37.1 12.0
DLCO/VA, %Pred 46.3 16.1
BL CT Score, %emph 38.5 12.8
Data is expressed as mean ± standard deviation
Demographics of the entire cohort of 148 FORTE Study Participants.Page 3 of 13
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Fiberoptic bronchoscopy was performed on an outpatient
basis in the endoscopy units of the participating centers of
this trial as per standard protocol. All participants,
received albuterol 2.5 mg and atrovent 1.0 mg by hand
held nebulizer prior to their bronchoscopy. During the
procedure, participants had continuous monitoring of
pulse oximetry, vital signs and received oxygen via nasal
cannula as required. Local anesthesia was provided by
administering viscous lidocaine to the nasopharynx and
2% lidocaine instilled via the bronchoscope to the vocal
cords and tracheobronchial tree. Participants were sedated
by use of 2-5 mg of midazolam IV at the discretion of the
bronchoscopist. The bronchoscope was inserted nasally
when possible, and the oral route was used as a second
choice. BAL was performed by instilling 180-240 ml of
saline solution into the medial or lateral segment of the
right middle lobe, with a dwell time of up to 30 seconds,
followed by aspiration. A target goal was to obtain a
return of at least 60 ml of lavage fluid. Following bron-
choscopy, participants were observed with regular moni-
toring of oximetry and vital signs. Participants were
discharged after a minimum of 2 hours of observation,
once safe swallowing had returned and observations were
satisfactory. All were given an emergency contact number
and followed up within 2 weeks. Severe adverse events
were documented at the time of bronchoscopy and
reported promptly to the data safety monitoring board for
the trial.
Processing of Lung Lavage and Plasma Samples
The lung lavage fluid was filtered through a sterile 100-
micron nylon mesh (Falcon) to remove mucus and
debris. The fluid was then centrifuged at 200 × g for 15
Table 2: Demographics of Stable and Rapidly Progressive COPD Subjects.
Stable Rapid Decliners
Age 65.0 65.8
Male gender percentage 56.67 (17 out of 30) 62.5 (10 out of 16)
Cigarette pack-years 56.5 46.6
SGRQ total score 32.76 29.96
Baseline pulmonary function
FEV1% predicted 41.33 43.57
FVC % predicted 74.43 81.47
Bronchodilator response % change 10.59 9.56
DLCO % predicted 38.0 35.4
Table 3: Demographics of Normal Controls for Plasma.
Normal Controls for Lavage
N 8
Age 24.6 ± 4.0
Sex 62.5% Male
White 87.5%
African American 12.5%
Age is represented as mean ± standard error of measurement
Table 4: Demographics of Normal Controls for Lavage.
Normal Controls for Plasma
N 11
Age 53.8 ± 13.5
Sex 63.6% Male
Smoking history 36.4%
White 63.6%
African American 18.2%
Hispanic 18.2%
Age is represented as mean ± standard error of measurementPage 4 of 13
(page number not for citation purposes)
Respiratory Research 2009, 10:113 http://respiratory-research.com/content/10/1/113minutes at 4°C. The cellular pellet was processed for RNA
extraction and the lavage supernatant was aliquoted and
immediately frozen at -70°C to -80°C and stored on-site.
When ready for analysis, aliquots were shipped frozen to
testing sites for biomarker determination. Baseline
plasma samples were obtained from the study partici-
pants. Approximately 30 ml of blood was obtained via
venipuncture into three 10 ml heparinized tubes. These
tubes were then centrifuged at 200 × g for 8 minutes at
4°C. The plasma was transferred into labeled 1.5 ml tubes
and stored at -70°C to -80°C and stored on-site until they
were ready to be shipped as described above.
Pulmonary Function Testing
Pre- and post-bronchodilator pulmonary function testing
(PFT) was performed at the screening visit, at baseline, 3
month, 6 month and 9 month visits on all patients.
Spirometry was performed pre- and post-bronchodilator
at each visit while diffusing capacity (DLCO) was per-
formed post BD at each visit. Pre-BD testing was done at
least four hours after the use of short acting bronchodila-
tors (albuterol, fenoterol) and at least 12 hours after the
use of long-acting bronchodilators (theophylline or salm-
eterol). Post-BD testing took place at least 15 minutes and
no longer than 1 hour after 2 inhalations of albuterol.
Testing was completed within sixty minutes of bronchodi-
lator administration. Bronchodilators were administered
via a metered dose inhaler under the supervision of a
trained pulmonary function technologist. Spirometry was
performed in adherence to ATS recommendations[10,11].
Predicted values for FEV1 were based on the prediction
equations of Hankinson et al[11]. Single breath diffusing
capacity (DLCO) was performed following standard tech-
niques[12]. Normal reference values were derived from
those of Crapo and colleagues[13]. The mean of three
acceptable maneuvers is reported as the data point.
Cytokine Measurements
Plasma and lung lavage cytokines were measured using
the Luminex human cytokine multiplex-25 bead array
assay kit (Biosource, Camarillo, CA). This kit is able to
simultaneously measure human IL-1β, IL-1Ra, IL-2, IL-2R,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-
15, IL-17, TNF-α, IFN-α, IFN-γ, GM-CSF, MIP-1α, MIP-1β,
IP-10, MIG, Eotaxin-1, RANTES, and MCP-1. The 25 mul-
tiplex array was chosen since it would measure several
Th1/Th2 and eosinophil related cytokines. Standard
curves for each cytokine were generated by using the refer-
ence cytokine concentrations supplied in this kit. Incuba-
tion buffer (50 μL) and 1:2 diluted plasma or lung lavage
fluid samples or standards (50 μL) were pipetted into the
wells and incubated for 2 hours with the beads. All sam-
ples and standards were performed in duplicate. The wells
were then washed using a vacuum manifold and bioti-
nylated detector antibody was subsequently added. After
1 hour, the beads were washed again and then incubated
for 30 minutes with streptavidin conjugated to the fluo-
rescent protein, R-phycoerythrin (Streptavidin-RPE). After
washing to remove the unbound Streptavidin-RPE, the
beads (minimum of 50 beads per cytokine) were analyzed
using a Luminex 100 instrument (Upstate, Temecula, CA),
which monitored the spectral properties of the beads
while simultaneously measuring the amount of fluores-
cence associated with R-phycoerythrin. Raw data (mean
fluorescence intensity, MFI) were analyzed using Master-
Plex software (Upstate, Temecula, CA). Luminex analyses
focused specifically on plasma IL-2 and eotaxin-1 were
conducted on an additional twenty-three COPD subjects
and eight normal controls. These controls were repeat
samples from our first analyses that were utilized to dem-
onstrate reproducibility of our results. All luminex analy-
ses were conducted by Ocean Ridge Biosciences (ORB,
Jupiter, Florida).
Statistical Analysis
The results are presented as the mean ± standard error for
all variables that were examined. Analyses demonstrated
that variances were equal for measurements of IL-2 and
eotaxin-1. Comparisons between groups were done using
ANOVA for non-repeated measures and significance and
the null hypothesis was tested at the 5% level.
Results
Plasma Cytokine Levels in COPD Participants and Normal 
Controls
In our initial analyses, we examined twenty-five plasma
cytokine levels (IL-1β, IL-1Ra, IL-2, IL-2R, IL-4, -5, -6, -7, -
8, -10, -12p40/p70, -13, -15, -17, TNF-α, IFN-α, IFN-γ,
GM-CSF, MIP-1α, MIP-1β, IP-10, MIG, Eotaxin-1,
RANTES, MCP-1) and found that nineteen of these were
elevated in the COPD participants (n = 11) relative to age-
matched normal controls (n = 11) (Table 5). However,
this elevation was statistically significant (p < 0.05) when
compared to normals for only nine of these cytokines (IL-
4, -5, -7, -8, IFN-α, GM-CSF, MIP-1α, MIP-1β and IP-10).
IL-10 was the only cytokine that trended lower in the
COPD groups although this again did not reach statistical
significance.
Plasma Cytokine Levels in Stable or Progressive COPD
Initial multiplex analyses revealed that cytokine levels
were increased in individuals with stable COPD com-
pared to those with rapidly progressive COPD (Table 6).
These initial studies found that plasma IL-2 was signifi-
cantly increased in stable COPD subjects compared to
those with rapidly progressive disease while plasma
eotaxin-1 levels were significantly lower in stable COPD
subjects compared to controls. Confirmatory studies spe-Page 5 of 13
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Table 5: Comparisons between Plasma Cytokine Levels in COPD.
NORMALS (N = 11) EMPHYSEMA (N = 27) p value
IL-1β 151(55) 329(58) NS
IL-1Ra 1665(589) 2933(575) NS
IL-2* 27(11) 49(8) NS
IL-2R* 511(162) 631(95) NS
IL-4 21(9) 62(11) <0.04
IL-5 9(4) 26(5) <0.05
IL-6 47(17) 74(10) NS
IL-7 37(16) 97(13) <0.02
IL-8 10(2) 18(2) <0.04
IL-10 78(52) 47(10) NS
IL-12p40/p70 503(53) 590(60) NS
IL-13 17(9) 33(9) NS
IL-15 101(48) 171(26) NS
IL-17 46(24) 107(20) NS
TNF-α 69(22) 75(15) NS
IFN-α 70(41) 264(43) <0.02
IFN-γ 73(32) 158(26) NS
GM-CSF 192(71) 423(59) <0.04
MIP-1α 119(19) 192(20) <0.05
MIP-1β 831(235) 1771(230) <0.03
IP-10 60(12) 95(8) <0.04
MIG 505(247) 819(120) NS
EOTAXIN* 1043(237) 659(77) =0.06
RANTES 30969(4420) 33527(3411) NS
MCP-1 1931(158) 1776(98) NS
Plasma levels of 25 human cytokines were measured in COPD participants (n = 27) and age-matched normal controls (n = 11) using the Luminex 
25-plex assay. Additional analyses for plasma IL-2, IL-2R and Eotaxin-1 were conducted on 6 rapid decliners and 17 stable COPD subjects. 
Significant changes in cytokine levels were found in nine of the examined cytokines (indicated in bold, p < 0.05). Parentheses indicate standard error 
of measurement.
*N = 11 for normal controls and N = 50 for emphysema subjects
Data is reported as mean ± standard error of measurement
The standard error of measurement is in parentheses
Respiratory Research 2009, 10:113 http://respiratory-research.com/content/10/1/113cifically examining plasma IL-2, IL-2R and eotaxin-1 were
conducted on an additional 17 stable and 6 rapidly pro-
gressive COPD subjects. Individuals with stable COPD
had IL-2 plasma levels (Figure 3) that were nearly three-
fold increased compared to those with rapidly progressive
COPD (p = 0.04) and normal controls (p = 0.11). The lev-
els of IL-2 in the rapidly progressive COPD group were
comparable to the levels seen in the normal controls. In
contrast, there were no significant differences in IL-2R lev-
els between any of the study groups (Figure 4). However,
every COPD subject with a plasma IL-2 >100 pg/ml or IL-
2R >1500 pg/ml demonstrated a stable disease course.
Eotaxin-1 levels, on the other hand, were significantly
lower in the stable COPD group (Figure 5) compared to
normal controls (p < 0.03) and trended lower in stable
COPD subjects compared to those with rapidly progres-
sive disease (p = 0.11). Indeed, a plasma eotaxin-1 of
>1300 pg/ml was predictive of a more rapid disease pro-
gression.
Lung Lavage Cytokine Levels in COPD Patients and 
Controls
Of the twenty-five cytokines tested only eight (IL-1Ra, IL-
2, -6, -8, IP-10, RANTES, MCP-1 and eotaxin-1) had
detectable levels within the lung lavage. Eotaxin-1, how-
ever, was the only cytokine that differed significantly
amongst the groups tested (see Table 7). Eotaxin-1 levels
(Figure 6) were significantly higher in the rapidly progres-
sive cohort compared to the stable COPD group (p =
0.04) and to normal controls (p < 0.02). In addition, the
COPD participants as a group had significantly higher lev-
els of eotaxin-1 than normal controls (p < 0.01). Of note,
every COPD subject with a lavage eotaxin-1 level >50 pg/
ml demonstrated rapid disease progression. Elevations in
RANTES levels (Figure 7) were noted in both the stable
and rapid COPD groups; however, these differences were
not statistically significant.
Discussion
This study demonstrates that markers of T cell and eosi-
nophilic inflammation are predictive of disease progres-
sion of COPD. Individuals with stable disease have higher
plasma levels of IL-2 than those with rapidly progressive
COPD and lower plasma eotaxin-1 levels compared to
normal controls. In addition, those COPD subjects who
experienced a subsequent physiologic deterioration of
their disease had markedly higher lung lavage eotaxin-1
levels compared to subjects who demonstrated disease
stability over the same time interval. Together, these
results suggest that measuring IL-2 and eotaxin-1 levels
could enable physicians to identify those COPD patients
that require more intensive monitoring and treatment in
the future. Moreover, these findings indicate that cell-
mediated immune responses have an important effect on
the clinical status of this disease.
IL-2 is a Th1 derived cytokine that induces the prolifera-
tion and activation of both CD4+ and CD8+ lymphocytes.
While several recent studies, have implicated T lym-
phocytes in the pathogenesis[3,14] and functional
decline[15,16] of COPD, the exact role they play in this
disease remains ambiguous. In fact, activation of periph-
eral CD4+ cells correlates positively with lung function in
smokers[17]. Moreover, smokers with preserved lung
function have a prominent up-regulation of T regulatory
cells in the lung compared to never smokers and patients
IL-2 Levels are Increased in Stable COPD ParticipantsFigur  3
IL-2 Levels are Increased in Stable COPD Partici-
pants. Plasma levels of IL-2 were significantly increased in 
stable COPD participants (black squares, n = 34) compared 
to subjects with rapidly progressive COPD (black triangles, n 
= 1) (p = 0.04) and trended higher in stable COPD subjects 
compared to age-matched normal controls (black circles, n = 
11) (p = 0.11).
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IL-2R Levels in Stable and Rapidly Progressive 
Cohorts. Plasma levels of IL-2R were not significantly 
altered in any of the groups we examined though the highest 
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cytokine IL-2 was significantly elevated in the plasma of
COPD patients who demonstrated disease stability over a
six-month time period. Together, these data suggest that T
cell mediated immune responses can alter the physiologic
progression of this disease.
IL-2 may prevent disease progression by promoting virus-
specific CD4+ and CD8+ T-cell responses which deter
virus replication and thereby limit the damaging effects of
chronic viral infection in the lung[19]. CD8+ cells are
increased in the lungs of guinea pigs with latent adenovi-
ral infection[20] and this increase may act to reduce lung
inflammation by suppressing active viral infection[21].
Respiratory syncytial virus (RSV) diminishes the effector
activity of CD8+ cells and the development of CD8+ T cell
memory[22]. This effect, however, can be reversed by IL-
2[23] thus preventing recurrent infection with this com-
mon pathogen in patients with COPD[24,25]. In addition
to viruses, cytotoxic lymphocyte responses, which are
coordinated by CD4+ cells, exert an important role in
defending against H. influenza infections in the lung[26].
In fact, studies in mice demonstrate that cigarette smoke
alters T cell function which can render the animal more
susceptible to infection [27]. Thus, we postulate that
enhanced T cell responses in our stable COPD cohort may
have acted to prevent disease progression by limiting the
pathogenicity of bacterial and viral infections within the
lung.
Another means by which IL-2 may influence disease pro-
gression is by regulating the survival of T cells[28]. In cul-
ture, IL-2 promotes T cell survival in part by inducing the
expression of Bcl-2, a protein that protects from passive
apoptotic cell death (PCD)[29,30]. T lymphocyte apopto-
sis is increased both in the peripheral blood[31] and lung
lavage[32] of COPD patients. The loss of these T cells can
render the lung susceptible to infections[33,34] thereby
increasing the likelihood of disease exacerbations, an
important factor in the progression of the disease[35]. In
addition, the uncleared apoptotic cells can injure the lung
by releasing proteases and other harmful intracellular
contents[36]. These damaging effects are accentuated by
the fact that pulmonary macrophages from COPD
patients have a defect in their ability to phagocytose apop-
totic cells in the lung[37]. Conversely, it is conceivable
that IL-2 protects the lung by actually stimulating the
apoptosis of auto-reactive T lymphocytes. IL-2 has been
shown to program mouse lymphocytes for apoptosis and
mice deficient in IL-2Rα are resistant to Fas-mediated acti-
vation induced cell death (AICD)[38]. Activation induced
cell death is a critical process for maintaining self-toler-
ance[39]. IL-2 by activating AICD can eliminate autoreac-
tive T cells and prevent the development of inflammatory
responses to self antigens which are capable of generating
emphysematous changes in the lung[40].
In contrast to IL-2, increases in eotaxin-1 were associated
with disease progression in COPD. We found significant
increases in lung lavage eotaxin-1 levels in COPD patients
compared to normal controls. More importantly, those
patients whose lung function subsequently declined over
the ensuing six months had significantly higher lavage
eotaxin-1 levels than those subjects with stable lung func-
tion over the same time period. In addition, disease stabil-
ity was associated with decreased plasma eotaxin-1 levels.
Eotaxin-1 is a CC chemokine (CCL11) that binds to the
CC chemokine receptor 3 (CCR3) on the surface of eosi-
nophils thereby inducing eosinophil activation[41] and
migration[42]. Lung eosinophilia has been linked with
bronchial hyperreactivity in COPD patients[1]. Moreover,
the expression of both eotaxin-1 and CCR3 is up regulated
during exacerbations of chronic bronchitis[43] and
eotaxin-1 levels are associated with bronchodilator
response and the extent of emphysema on CT scans[44].
Coupled with these previous findings, our data indicate
that eotaxin-1-mediated lung eosinophilia may be a criti-
cal factor in the progression of this disease.
Eotaxin-1 Levels are Decreased in Subjects with Stable COPDFigure 5
Eotaxin-1 Levels are Decreased in Subjects with Sta-
ble COPD. Plasma levels of eotaxin-1 were significantly 
lower in stable COPD participants (black squares, n = 34) 
compared to age-matched normal controls (black circles, n = 
11) (p < 0.04). In addition, subjects with rapidly progressive 
COPD (black triangles, n = 16) tended to have higher levels 
compared to those with stable disease though this difference 
did not reach statistical significance (p = 0.11).
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Table 6: Comparison of Plasma Cytokine Levels between Rapid Decliners Stable COPD Participants and Normal Controls.
NORMALS (N = 11) STABLE (N = 17) DECLINERS (N = 10) p value Stable vs. 
Rapid
p value Stable vs. 
Normals
IL-1β 151(55) 414(104) 184(61) <0.06 <0.03
IL-1Ra 1665(589) 3514(1078) 1945(598) NS NS
IL-2* 28(12) 62(11) 25(7) <0.04 =0.10
IL-2R* 511(162) 700(128) 495(97) NS NS
IL-4 21(9) 70(22) 48(11) NS <0.04
IL-5 9(4) 32(9) 16(4) NS <0.03
IL-6 47(17) 85(20) 56(10) NS NS
IL-7 37(16) 101(25) 97(13) NS <0.03
IL-8 10(2) 20(4) 15(2) NS <0.03
IL-10 78(52) 51(17) 40(16) NS NS
IL-12p40/p70 503(53) 592(117) 586(58) NS NS
IL-13 17(9) 42(16) 19(8) NS NS
IL-15 101(48) 203(51) 117(20) NS NS
IL-17 46(24) 123(38) 80(18) NS NS
TNF-α 69(22) 88(28) 53(12) NS NS
IFN-α 70(41) 308(83) 188(48) NS <0.02
IFN-γ 73(32) 187(50) 109(22) NS <0.05
GM-CSF 192(71) 463(120) 356(63) NS <0.05
MIP-1α 119(19) 206(36) 168(30) NS <0.04
MIP-1β 831(235) 1976(431) 1422(243) NS <0.03
IP-10 60(12) 88(11) 106(18) NS <0.05
MIG 505(247) 941(235) 610(87) NS NS
EOTAXIN* 1043(237) 572(128) 834(164) =0.11 <0.04
RANTES 30969(4420) 30066(4135) 39411(7420) NS NS
MCP-1 1931(158) 1771(181) 1785(129) NS NS
*N = 34 stable COPD subjects, 16 rapid COPD subjects and 11 normal controls
Data is reported as mean ± standard error of measurement
The standard error of measurement is in parentheses
Plasma cytokine levels were measured as above in stable COPD participants (n = 17) and COPD participants who demonstrated rapid decline in 
the first six months of the trial (n = 10). For IL-2, IL-2R and Eotaxin-1 plasma levels were determined in an additional 6 rapid decliner and 17 stable 
COPD subjects. IL-2 was the one cytokine that was significantly increased in stable COPD subjects compared to rapid decliners (indicated in bold, 
p < 0.05). Parentheses indicate standard error of measurement.
Respiratory Research 2009, 10:113 http://respiratory-research.com/content/10/1/113It is important to note that all the study participants at
baseline were former smokers who were clinically stable
and had no signs of exacerbation or recent infection. In
fact, the presence of an exacerbation was an exclusion cri-
terion for the trial. Thus, we cannot ascribe the subse-
quent decline in FEV1 in the rapid decliners to the
presence of disease exacerbation or inherent differences
with the stable COPD cohort. Indeed, both the rapid
decliners and stable COPD subjects selected for these
studies had GOLD IIB disease with visual evidence of
emphysema occupying ≤ 10% of the lung on CT scan. The
subjects did not use steroids for at least two months prior
to study entry and did not have excessive airway hyperre-
activity during bronchodilator testing. Similarly, our
study findings cannot be attributed to the study drug-
retinoic acid. Plasma and lavage measurements were
taken at baseline prior to initiation of retinoic acid and
retinoic acid itself had no impact on any of the physio-
logic, radiographic or quality of life measures at the six or
nine-month time point[9].
Given the multiple analyses that were conducted it is con-
ceivable that the changes in IL-2 may have occurred by
chance. However, further plasma IL-2 analyses on an
additional 6 rapid decliners and 17 stable COPD subjects
confirmed the differences between these two groups.
However, prospective analyses will be needed to validate
these results and determine if these findings can be extrap-
olated to a more heterogeneous population of COPD sub-
jects. A strength of this study is that it contains both
plasma and lung lavage analyses on a well-characterized
cohort of previously stable advanced emphysema sub-
jects. The literature regarding the impact of T cell and eosi-
nophil related cytokines in advanced emphysema is
limited-particularly for lung lavage. In fact, this is one of
the only studies to examine the relationship between a
lung lavage biomarker and subsequent rate of decline of
lung function in COPD[45]. Thus, our findings provide
important novel evidence that these cell types are
involved in the progression of the disease.
Conclusion
In summary, in this study we have identified distinct dif-
ferences in cytokines levels in advanced emphysema
patients whose disease progressed rapidly over a six-
month time period. The changes in IL-2 and eotaxin-1
suggest that alterations in T lymphocyte and eosinophil
trafficking in the lung could be important factors affecting
the stability of this disease. If confirmed in a larger pro-
spective trial, these results could lead to the development
of useful clinical biomarkers that could accurately predict
the future course of the disease. This would not only per-
Lung Lavage RANTES Levels in COPD Subjects, Asthmatics and Normal ControlsFigure 7
Lung Lavage RANTES Levels in COPD Subjects, 
Asthmatics and Normal Controls. Lung lavage RANTES 
levels were measured in stable COPD participants (black 
squares, n = 11), rapidly progressive COPD participants 
(black triangles, n = 9) and normal controls (black circles, n = 
8) using the Luminex 25-plex assay. Increases were seen in 
both cohorts of COPD; however, these differences did not 
reach statistical significance.
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Lung Lavage Eotaxin-1 Levels in COPD Subjects, Asthmatics and Normal ControlsFigure 6
Lung Lavage Eotaxin-1 Levels in COPD Subjects, 
Asthmatics and Normal Controls. Lung lavage Eotaxin-1 
levels measured using the Luminex 25-plex assay were signif-
icantly higher in rapidly progressive COPD participants 
(black triangles, n = 9) compared to normal controls (black 
circles, n = 8) (p < 0.03). In addition, levels in participants 
with rapidly progressive COPD had higher levels than partic-
ipants with stable COPD (black squares, n = 11) (p < 0.05).
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Respiratory Research 2009, 10:113 http://respiratory-research.com/content/10/1/113mit clinicians to ascertain which patients require closer
observation but would also provide researchers with a sur-
rogate endpoint to detect clinically important responses
to therapies.
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